Phase I, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Study type: Interventional What is this?
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase: I What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
- Rochester, Minnesota: 12-007863
NCT ID: NCT01707264
Sponsor Protocol Number: NEOD001-001
About this study
Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30 subjects with AL amyloidosis. Expansion phase to evaluate safety, efficacy and pharmacokinetics of NEOD001 in 20 additional subjects at the maximum tolerated dose.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.
See eligibility criteria
- Males and females aged ≥18 years;
- ECOG performance status (PS) 0-2;
- Diagnosis of systemic AL amyloidosis (subjects with non-AL amyloidosis are not eligible);
- Received at least one prior systemic therapy, which may include stem cell transplant, for AL amyloidosis;
- Have adequate organ function;
- Ability to understand and willingness to sign informed consent prior to initiation of any study procedures.
- Secondary or familial amyloidosis;
- Life expectancy of < 3 months;
- Symptomatic multiple myeloma;
- Hypersensitivities to other monoclonal antibodies;
- Known HIV infection;
- Women who are lactating;
- Any other condition or prior therapy, which in the opinion of the PI, would make the subject unsuitable for the study.
Participating Mayo Clinic locations
Study statuses change often. Please contact us for help.
|Mayo Clinic Location
Mayo Clinic principal investigator
Morie Gertz, M.D.
Closed for enrollment
Cancer Center Clinical Trials Referral Office